Loading...
XLONHVO
Market cap168mUSD
Dec 24, Last price  
19.50GBP
1D
0.25%
1Q
-33.22%
Jan 2017
-3.20%
IPO
-38.83%
Name

Venn Life Sciences Holdings

Chart & Performance

D1W1MN
XLON:HVO chart
P/E
823.29
P/S
236.73
EPS
0.02
Div Yield, %
0.02%
Shrs. gr., 5y
56.84%
Rev. gr., 5y
34.89%
Revenues
56m
+15.61%
2,870,8322,193,2581,704,1133,814,9108,467,44715,265,70615,451,18112,548,7003,284,05520,602,00036,864,00048,477,00056,043,000
Net income
16m
P
1,010,92700011,069453,479000-10,791,000-74,000-776,00016,115,000
CFO
17m
+7.87%
907,413000000004,171,000-1,564,00015,981,00017,239,000
Dividend
Apr 18, 20240.17253 GBP/sh
Earnings
Apr 07, 2025

Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
URL
https://hvivo.com/
IPO date
Dec 14, 2012
Employees
210
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
56,043
15.61%
48,477
31.50%
36,864
78.93%
Cost of revenue
69,799
68,099
18,824
Unusual Expense (Income)
NOPBT
(13,756)
(19,622)
18,040
NOPBT Margin
48.94%
Operating Taxes
(4,968)
411
351
Tax Rate
1.95%
NOPAT
(8,788)
(20,033)
17,689
Net income
16,115
-2,176.68%
(776)
948.65%
(74)
-99.31%
Dividends
(3,054)
Dividend yield
1.87%
Proceeds from repurchase of equity
521
3
40
BB yield
-0.32%
0.00%
-0.03%
Debt
Debt current
367
826
2,285
Long-term debt
24,693
2,300
3,717
Deferred revenue
Other long-term liabilities
1,559
660
40
Net debt
(11,913)
(25,318)
(16,697)
Cash flow
Cash from operating activities
17,239
15,981
(1,564)
CAPEX
(5,177)
(1,362)
(739)
Cash from investing activities
(5,177)
(1,362)
(739)
Cash from financing activities
(3,523)
(1,834)
(1,195)
FCF
(25,703)
(19,441)
19,272
Balance
Cash
36,973
28,444
15,694
Long term investments
7,005
Excess cash
34,171
26,020
20,856
Stockholders' equity
40,666
27,070
27,535
Invested Capital
14,244
(4,317)
2,155
ROIC
1,853.23%
80.01%
ROCE
78.40%
EV
Common stock shares outstanding
685,847
670,944
670,187
Price
0.24
137.50%
0.10
-56.52%
0.23
-0.34%
Market cap
162,889
142.78%
67,094
-56.47%
154,143
11.33%
EV
150,976
41,776
137,446
EBITDA
(11,040)
(16,692)
20,605
EV/EBITDA
6.67
Interest
176
133
227
Interest/NOPBT
1.26%